Alto Ingredients, Inc. announced a net income of $12.7 million and adjusted EBITDA of $21.0 million for Q3 2026, supported by strong core operations and Section 45Z tax credits. The company reduced debt by $6.5 million during the quarter and is expanding production capacity through capital projects. Alto expects at least $20 million in 45Z tax credits for 2026 and is working on agreements to secure low carbon intensity corn supply. Industry tailwinds like increased ethanol demand and E15 adoption in California support its growth and profitability outlook.
Alto Ingredients, Inc. reported a net income of $12.7 million for Q3 2026, reflecting strong operational performance and tax credit benefits. For readers following the broader US stock market, here is Pluang's market snapshot as of Nov 05, 2026 01:21 WIB: out of 150 priced US stocks, 121 rose and 29 fell today. Notable movers include CVNA at USD 78.37 with a 9.95% increase and Pluang order activity of 88% Sell / 12% Buy, MMM at USD 194.37 up 9.78% with 39% Sell / 61% Buy, and NEM at USD 116.99 rising 8.86% with 53% Sell / 47% Buy.
NOVAGOLD shareholders approved a transaction for New NOVAGOLD to acquire the remaining 40% interest in the Donlin Gold project from Paulson Advisers, increasing NOVAGOLD's ownership from 60% to 100%. This consolidation makes New NOVAGOLD the ultimate...
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, focusing on de-risked, post-proof-of-concept assets. The company offers investors exposure to blockbuster therapies with attractive risk-adjusted returns, including aro...
